MUCOSAL IMMUNOLOGY
LOCAL CHAPTER
NYC

MAY 6, 2019
11:30am – 6:00pm

HOSTED BY
Well Cornell Medicine
Jill Roberts Institute for Research in Inflammatory Bowel Disease
11:30am-12:00 COFFEE AND REGISTRATION

12:00-12:15pm WELCOME FROM THE ORGANIZERS

Iliyan Iliev, PhD
Assistant Professor of Immunology in Medicine
Weill Cornell Medicine

Gregory Sonnenberg, PhD
Associate Professor of Microbiology and Immunology in Medicine
Weill Cornell Medicine

OPENING REMARKS

David Artis, PhD
Michael Kors Professor of Immunology
Director, Jill Roberts Institute for Research in Inflammatory Bowel Disease
Weill Cornell Medicine

12:15-1:00pm KEYNOTE TALK

Miriam Merad, MD, PhD
Director of the Precision Immunology Institute
Professor of Oncological Sciences and Medicine
Mount Sinai Chair in Cancer Immunology
Director of Human Immune Monitoring Center
Icahn School of Medicine at Mount Sinai

1:00 pm SESSION 1 WITH CHAIRS DRS. CHUN-JUN GUO AND MONICA VILADOMIU-PUJOL

1:00-1:15pm Simone Becattini, PhD
Transcriptional adaptation of intestinal bacteria to host immune responses
Pamer Lab / Memorial Sloan Kettering Cancer Center

1:15-1:30pm Jessica Neil, PhD
IFN-I and IL-22 mediate protective effects of intestinal viral infection
Cadwell Lab / Skirball Institute at New York University

1:30-1:45pm Orchi Dutta
Dectin-1 regulates the production of type I and III interferons for optimal pulmonary antifungal immunity
Rivera Lab / Rutgers University

1:45-2:00pm Anne-Laure Flamar, PhD
Interleukin-33-mediated induction of the enzyme tryptophan hydroxylase 1 promotes inflammatory ILC2 responses and type 2 immunity
Artis Lab / Weill Cornell Medicine

2:00-2:15pm Lei Zhou, PhD
Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2
Sonnenberg Lab / Weill Cornell Medicine
2:15-2:50pm  COFFEE BREAK

2:50pm  SESSION 2 WITH CHAIRS DRs. MELODY ZENG AND IRINA LEONARDI

2:50-3:05pm  Lili Chen, PhD
Diet Modifies Colonic Microbiota and CD4+ T Cell Repertoire to Trigger Flares in a Novel Model of Colitis Induced by IL-23
Lira Lab / Icahn School of Medicine at Mount Sinai

3:05-3:20pm  Leandro Pires Araujo, PhD
Endocytosis of commensal antigens by intestinal epithelial cells regulates mucosal T cell homeostasis
Ivanov Lab / Columbia University

3:20-3:35pm  Clarissa Campbell Menezes, PhD
Transformation of bile acids by intestinal bacteria promotes extrathymic Treg cell generation
Rudensky Lab / Memorial Sloan Kettering Cancer Center

3:35-3:50pm  Angelina M. Bilate, PhD
Lymphocyte plasticity at the intestinal border: the importance of carrying a T cell receptor
Mucida Lab / The Rockefeller University

3:50-4:05pm  Graham Britton, PhD
Modelling therapeutic fecal microbiota transplantation in mice colonized with human inflammatory bowel disease microbitas
Faith Lab / Icahn School of Medicine at Mount Sinai

4:05-4:50pm  KEYNOTE TALK

Dan Littman, MD, PhD
Helen L. and Martin S. Kimmel Professor of Molecular Immunology in Department of Pathology
Professor, Department of Microbiology
Skirball Institute at New York University

5:00pm  RECEPTION

THANKS TO THE SESSION CHAIRS:

Chun-Jun Guo, PhD
Assistant Professor of Immunology in Medicine
Weill Cornell Medicine

Monica Viladomiu-Pujol, PhD
Postdoctoral Associate in Medicine
Longman Lab / Weill Cornell Medicine

Melody Zeng, PhD
Assistant Professor of Immunology in Pediatrics
Weill Cornell Medicine

Irina Leonardi, PhD
Postdoctoral Associate in Medicine
Iliev Lab / Weill Cornell Medicine
Dr. Dan Littman received his PhD and MD from Washington University in 1980 and was a postdoctoral fellow in Richard Axel’s laboratory at Columbia University. He was Professor of Microbiology and Immunology at the University of California, San Francisco, before joining NYU, where he is the Kimmel Professor of Molecular Immunology at the Skirball Institute and an Investigator of the Howard Hughes Medical Institute. Dr. Littman is a member of the U.S. National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences, past president of the American Association of Immunologists, and recipient of several scientific awards, including the Ross Prize in Molecular Medicine and the Vilcek Prize in Biomedical Sciences. His laboratory applies molecular and genetics tools to study how T lymphocytes develop and participate in inflammation and how commensal microbiota influence immune homeostasis and pathogenesis.

Miriam Merad, M.D., Ph.D. is the Mount Sinai Endowed Professor in Cancer Immunology and the Director of the Precision Immunology Institute at Icahn School of Medicine at Mount Sinai in New York. Dr. Merad also co-Directs the Cancer Immunology program at The Mount Sinai Tisch Cancer Institute and is the Director of the Mount Sinai Human Immune Monitoring Center (HIMC).

Dr. Merad’s laboratory made seminal discoveries to our understanding of the mechanisms that control the development and functional identity of tissue resident dendritic cells and macrophages during homeostasis, and examines how these regulations are changed in cancer and inflammatory diseases. The overarching goal of her laboratory is to identify dysregulated pathways in macrophages and dendritic cells that can be harnessed to treat cancer using both genetically engineered mouse models and human lesions to address these questions. To expand the understanding of immune cells contribution to human lesions, she founded the Human Immune Monitoring Center at Mount Sinai in 2009 to implement technology platforms to maximize information obtained from limited biological samples. In 2016, she took the leadership of the Precision Immunology Institute at the Icahn School of Medicine (PrIISM) to continue to lead initiatives to enhance human immunology science. PrIISM integrates immunological research programs across 42 laboratories with synergistic expertise in biology, medicine, technology, physics, mathematics and computational biology, which come together to frame novel questions to understand the contribution of immune cells to disease initiation, progression and response to treatment, to implement cutting edge technologies and to develop novel immunotherapy strategies for the treatment of human diseases. Dr. Merad has authored more than 170 primary papers and reviews in high profile journals. She receives generous funding from the National Institutes of Health (NIH) for her research on innate immunity and its contribution to human disease, and belongs to several NIH consortia. In 2018, Dr. Merad received the William B. Coley Award for Distinguished Research in Tumor Immunology. She is an elected member of the American Society of Clinical Investigation, and lectures around the world on her work.